文献速递基础与转化研究临床试验与 GCP

一种安全有效的抗CD19 CAR T细胞疗法

A safe and potent anti-CD19 CAR T cell therapy.
PubMed 文献 · Nat Med · 2019-04-22

研究构建了源自CD19-BBz原型、含4-1BB与CD3ζ共刺激结构域的新型抗CD19 CAR分子CD19-BBz(86),其CAR T细胞细胞因子分泌更低、抗凋亡分子表达更高、增殖更慢但保留强细胞毒活性。1期试验中11例接受2×10^8-4×10^8剂量CD19-BBz(86) CAR T细胞的B细胞淋巴瘤患者有6例(54.5%)达完全缓解,25例治疗患者均未发生神经毒性或1级以上CRS。

要点

  • CD19-BBz(86) CAR T细胞较原型细胞因子分泌更低、抗凋亡分子更高、增殖更慢但细胞毒活性保留。
  • 11例接受2×10^8-4×10^8剂量CD19-BBz(86) CAR T细胞的B细胞淋巴瘤患者中6例(54.5%)达完全缓解。
  • 25例治疗患者均未发生神经毒性或1级以上细胞因子释放综合征,输注后血清细胞因子水平无显著升高。

核心结论

  • CD19-BBz(86) CAR T细胞疗法产生强效持久的抗淋巴瘤反应,且不引起神经毒性或严重细胞因子释放综合征,代表一种安全有效的抗CD19 CAR T细胞疗法。

研究设计与样本

  • 构建源自含4-1BB与CD3ζ共刺激结构域CD19-BBz原型的的新型抗CD19 CAR分子CD19-BBz(86),并在B细胞淋巴瘤患者中开展1期试验(ClinicalTrials.gov标识NCT02842138)。

主要发现

  • CD19-BBz(86) CAR T细胞较原型CD19-BBz CAR T细胞产生更低水平细胞因子、表达更高水平抗凋亡分子、增殖更慢,但保留强细胞毒活性。
  • 11例接受2×10^8-4×10^8 CD19-BBz(86) CAR T细胞剂量的患者中6例(54.5%)达完全缓解。
  • 25例治疗患者均未发生神经毒性或1级以上细胞因子释放综合征。
  • 治疗患者(包括达完全缓解者)CAR T细胞输注后血清细胞因子水平未检测到显著升高。
  • CD19-BBz(86) CAR T细胞在体内持续增殖并分化为记忆细胞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1BB and CD3ζ domains. We found that CD19-BBz(86) CAR T cells produced lower levels of cytokines, expressed higher levels of antiapoptotic molecules and proliferated more slowly than the prototype CD19-BBz CAR T cells, although they retained potent cytolytic activity. We performed a phase 1 trial of CD19-BBz(86) CAR T cell therapy in patients with B cell lymphoma (ClinicalTrials.gov identifier NCT02842138 ). Complete remission occurred in 6 of 11 patients (54.5%) who each received a dose of 2 × 108-4 × 108 CD19-BBz(86) CAR T cells. Notably, no neurological toxicity or CRS (greater than grade 1) occurred in any of the 25 patients treated. No significant elevation in serum cytokine levels after CAR T cell infusion was detected in the patients treated, including in those who achieved complete remission. CD19-BBz(86) CAR T cells persistently proliferated and differentiated into memory cells in vivo. Thus, therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Ying Z, Huang XF, Xiang X, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019. PMID: 31011207. doi:10.1038/s41591-019-0421-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。